Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Sarcoma
Interventions
Drug: O6-benzylguanine
Drug: carmustine
First Posted Date
2004-04-12
Last Posted Date
2013-09-05
Lead Sponsor
University of Chicago
Target Recruit Count
12
Registration Number
NCT00005066
Locations
🇺🇸

Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

🇺🇸

Division of Hematology/Oncology, Park Ridge, Illinois, United States

🇺🇸

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

and more 7 locations

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

First Posted Date
2004-04-08
Last Posted Date
2023-10-06
Lead Sponsor
University of Nebraska
Target Recruit Count
68
Registration Number
NCT00080886
Locations
🇺🇸

University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-04-07
Last Posted Date
2018-06-27
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
82
Registration Number
NCT00003176
Locations
🇺🇸

Simmons Cancer Center - Dallas, Dallas, Texas, United States

🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 7 locations

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-04-05
Last Posted Date
2013-04-08
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Registration Number
NCT00014573
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Lymphoma
Leukemia
First Posted Date
2004-03-31
Last Posted Date
2019-10-17
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
35
Registration Number
NCT00003402
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-03-26
Last Posted Date
2018-08-17
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
35
Registration Number
NCT00002461
Locations
🇺🇸

Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-02-16
Last Posted Date
2013-01-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00003632
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2004-02-12
Last Posted Date
2023-09-01
Lead Sponsor
University of Nebraska
Target Recruit Count
44
Registration Number
NCT00007852
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 1
Withdrawn
Conditions
Breast Cancer
First Posted Date
2004-02-12
Last Posted Date
2018-05-16
Lead Sponsor
Beth Israel Deaconess Medical Center
Registration Number
NCT00006123
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 3
Conditions
Lymphoma
First Posted Date
2004-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Lymphoma Trials Office
Target Recruit Count
500
Registration Number
NCT00003578
Locations
🇨🇿

Charles University Hospital, Prague (Praha), Czech Republic

🇬🇧

City Hospital - Birmingham, Birmingham, England, United Kingdom

🇳🇴

Norwegian Radium Hospital, Oslo, Norway

and more 69 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy